Wetherby Asset Management Inc. boosted its stake in shares of AstraZeneca plc (NYSE:AZN) by 5.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 37,809 shares of the company’s stock after acquiring an additional 1,933 shares during the quarter. Wetherby Asset Management Inc.’s holdings in AstraZeneca were worth $1,312,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Virtu Financial LLC bought a new stake in AstraZeneca during the fourth quarter worth approximately $246,000. Bank of New York Mellon Corp increased its stake in AstraZeneca by 1.2% during the fourth quarter. Bank of New York Mellon Corp now owns 220,883 shares of the company’s stock worth $7,665,000 after acquiring an additional 2,539 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its stake in shares of AstraZeneca by 50.7% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 171,382 shares of the company’s stock valued at $5,947,000 after buying an additional 57,669 shares during the last quarter. First Allied Advisory Services Inc. grew its stake in shares of AstraZeneca by 7.6% during the fourth quarter. First Allied Advisory Services Inc. now owns 23,845 shares of the company’s stock valued at $825,000 after buying an additional 1,694 shares during the last quarter. Finally, D.A. Davidson & CO. grew its stake in shares of AstraZeneca by 11.6% during the fourth quarter. D.A. Davidson & CO. now owns 18,509 shares of the company’s stock valued at $642,000 after buying an additional 1,931 shares during the last quarter. 14.91% of the stock is currently owned by institutional investors.
AstraZeneca plc (AZN) opened at $33.93 on Monday. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $85,937.57, a P/E ratio of 14.32, a P/E/G ratio of 2.05 and a beta of 0.70. AstraZeneca plc has a 52 week low of $28.43 and a 52 week high of $36.70.
The business also recently announced a semiannual dividend, which will be paid on Monday, March 19th. Shareholders of record on Friday, February 16th will be issued a dividend of $0.95 per share. The ex-dividend date of this dividend is Thursday, February 15th. This represents a yield of 5.62%. AstraZeneca’s dividend payout ratio is currently 57.81%.
A number of research firms have recently commented on AZN. BMO Capital Markets reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Sunday, February 4th. Leerink Swann upped their target price on AstraZeneca from $36.00 to $38.00 and gave the company a “market perform” rating in a research note on Tuesday, February 6th. ValuEngine raised AstraZeneca from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 3rd. Sanford C. Bernstein upped their target price on AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a research note on Monday, February 5th. Finally, Zacks Investment Research cut AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $35.20.
COPYRIGHT VIOLATION NOTICE: This piece was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2018/02/19/wetherby-asset-management-inc-has-1-31-million-holdings-in-astrazeneca-plc-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.